Results 11 to 20 of about 39,038 (256)

Oral diabetes medication monotherapy and short-term mortality in individuals with type 2 diabetes and coronary artery disease [PDF]

, 2018
Objective To determine whether sulfonylurea use, compared with non-sulfonylurea oral diabetes medication use, was associated with 2-year mortality in individuals with well-controlled diabetes and coronary artery disease (CAD). Research design and methods
Berkowitz, Seth A, Caplan, Liron, Grunwald, Gary K, Liu, Wenhui G, Maddox, Thomas M, Raghavan, Sridharan, Reusch, Jane E.B, Saxon, David R   +7 more
core   +3 more sources

Differential interaction of glimepiride and glibenclamide with the β-cell sulfonylurea receptor I. Binding characteristics [PDF]

, 1994
Glimepiride is a novel sulfonylurea drug for treatment of non-insulin-dependent diabetes mellitus with higher blood sugar lowering efficacy in diabetic patients than glibenclamide raising the question whether this characteristics is in line with ...
Aguilar-Bryan, Ashcroft, Ashcroft, Benovic, Bhathena, Boyd, Boyd, Boyd, Carpentier, Chick, French, Gaines, Geisen, Geisen, Gerich, Gylfe, Kaubisch, Kolterman, Kramer, Kramer, Müller, Nelson, Nelson, Niki, Niki, Niki, Niki, Panten, Popov, Praz, Schmid-Antomarchi, Schmid-Antomarchi, Sturgess, Sugiura, Weiland, Yalow   +35 more
core   +1 more source

Incretin hormone responses to carbohydrate and protein/fat are preserved in adults with sulfonylurea‐treated KCNJ11 neonatal diabetes

Journal of Diabetes Investigation, 2023
The incretin hormones glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP), are thought to be the main drivers of insulin secretion in individuals with sulfonylurea (SU)‐treated KCNJ11 permanent neonatal diabetes.
Pamela Bowman, Kashyap A Patel, Timothy J McDonald, Jens J Holst, Bolette Hartmann, Maria Leveridge, Beverley M Shields, Suzie Hammersley, Steve R Spaull, Bridget A Knight, Sarah E Flanagan, Maggie H Shepherd, Rob C Andrews, Andrew T Hattersley   +13 more
doaj   +1 more source

Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia [PDF]

, 2011
OBJECTIVE: Lactic acidosis has been associated with use of metformin. Hypoglycemia is a major concern using sulfonylureas. The aim of this study was to compare the risk of lactic acidosis and hypoglycemia among patients with type 2 diabetes using oral ...
Bodmer, Michael, Jick, Susan S., Krähenbühl, Stephan, Meier, Christian, Meier, Christoph R.   +4 more
core   +2 more sources

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Adsorption of nicosulfuron herbicide in the agricultural soils of Bosnia and Herzegovina

Plant, Soil and Environment, 2020
In this study, the sorption characteristics of nicosulfuron herbicide in soils from different agricultural regions of Bosnia and Herzegovina, as well as factors influencing the sorption process, were evaluated.
Amer Sunulahpašić, Siniša Mitrić, Dragana Šunjka, Mirjana Žabić, Tihomir Predić, Milan Šipka, Luka Rodić   +6 more
doaj   +1 more source

Dynamics of total volume of pancreatic α‐ and β ‐cells under the influence sulfonylureas and their combination with dipeptidyl peptidase‐4 inhibitors

Endocrinology, Diabetes & Metabolism, 2021
Objective Sulfonylureas and dipeptidyl peptidase‐4 inhibitors have a multidirectional effect on pancreatic cells. We aimed to evaluate the effects of these drugs on β‐ and α‐cells in rats aged 12 months with type 2 diabetes mellitus when administered in ...
Tuchina Taisiia Pavlovna, Skotnikova Kseniia Petrovna, Vtorushina Anna Anatolievna, Uskov Ivan Sergeyevich, Rogoza Olga Vladimirovna, Grozov Roman Viktorovich, Babenko Alina Yurievna, Galagudza Mikhail Mikhailovich   +7 more
doaj   +1 more source

Differential interaction of glimepiride and glibenclamide with the β-cell sulfonylurea receptor II [PDF]

, 1994
Glimepiride is a novel sulfonylurea for the treatment of type II-diabetic patients exhibiting different receptor binding kinetics to β-cell membranes with 8–9-fold higher koff rate and 2.5–3-fold higher kon rate compared to glibenclamide (see ...
Aguilar-Bryan, Aguilar-Bryan, Ashcroft, Bayley, De Weille, Ehle, Galizzi, Geisen, Geisen, Glossmann, Glossmann, Hogg, Hollemans, Kramer, Kramer, Kramer, Kramer, Martyr, Müller, Nelson, Nelson, Niki, Ozanne, Panten, Pomerantz, Repke, Schmid-Antomarchi, Schwanstecher, Skeer, Wessel   +29 more
core   +1 more source

Reasoned opinion on the review of the existing maximum residue levels (MRLs) for mesosulfuron according to Article 12 of Regulation (EC) No 396/2005 [PDF]

EFSA Journal, 2012
According to Article 12 of Regulation (EC) No 396/2005, the European Food Safety Authority (EFSA) has reviewed the Maximum Residue Levels (MRLs) currently established at European level for the pesticide active substance mesosulfuron.
European Food Safety Authority
doaj   +1 more source

Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes

Journal of Diabetes Investigation, 2019
Aims/Introduction We investigated the difference in efficacy and safety between discontinuation and maintaining of sulfonylurea when adding a sodium–glucose cotransporter 2 inhibitor.
Kiyohiko Takahashi, Kyu Yong Cho, Akinobu Nakamura, Aika Miya, Arina Miyoshi, Chiho Yamamoto, Hiroshi Nomoto, Hirokatsu Niwa, Kiyohito Takahashi, Naoki Manda, Yoshio Kurihara, Shin Aoki, Yoichi M Ito, Tatsuya Atsumi, Hideaki Miyoshi   +14 more
doaj   +1 more source